Sep-17 -

Imaging / Breast Group

EORTC 10041 – MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid Chemo Therapy): A prospective, randomized study comparing the 70-gene signature with the common clinicopathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.

From 2007 to 2011, EORTC enrolled 6 693 breast cancer patients from 112 hospitals across 9 countries. This EORTC study found that the 70-gene signature MammaPrint® is an effective prognostic assessment tool for patients with node-negative or 1-3 node positive early-stage breast cancer. These patients can be safely spared adjuvant chemotherapy (post-operation), without affecting their long term outcome. This finding could substantially optimize the use of additional chemotherapy, sparing unnecessary toxicities in patients. This breakthrough clinical trial is an example of international, academic, and multi-disciplinary leadership and achievement in breast cancer research. It is also a clear illustration of an integrated public, private and patient group collaboration.


Go to Top